My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 118

    1.

    Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.

    Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

    Diabetes. 2008 Sep;57(9):2288-95. Epub 2008 Jun 5.PMID: 18535187 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.

    Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA.

    Int J Obes Relat Metab Disord. 2004 Jun;28(6):783-9.PMID: 15024400 [PubMed - indexed for MEDLINE]Related articles

    7.

    Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.

    Carey PE, Gerrard J, Cline GW, Dalla Man C, English PT, Firbank MJ, Cobelli C, Taylor R.

    Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E941-7. Epub 2005 Jul 5.PMID: 15998660 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

    van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

    Circulation. 2009 Apr 21;119(15):2069-77. Epub 2009 Apr 6.PMID: 19349323 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.

    Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M.

    Metabolism. 2007 Oct;56(10):1418-24.PMID: 17884455 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

    Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.

    Am J Med. 2001 Jul;111(1):10-7.PMID: 11448655 [PubMed - indexed for MEDLINE]Related articles

    11.

    Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.

    Diabetes. 2008 Jan;57(1):24-31. Epub 2007 Oct 3.PMID: 17914032 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

    Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E.

    Clin Pharmacol Ther. 2007 Feb;81(2):205-12.PMID: 17259945 [PubMed - indexed for MEDLINE]Related articles

    13.

    Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

    Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA.

    Gastroenterology. 2007 Aug;133(2):496-506. Epub 2007 May 1.PMID: 17681171 [PubMed - indexed for MEDLINE]Related articles

    14.

    Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.

    Ravikumar B, Carey PE, Snaar JE, Deelchand DK, Cook DB, Neely RD, English PT, Firbank MJ, Morris PG, Taylor R.

    Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E789-97. Epub 2004 Nov 30.PMID: 15572652 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

    Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, Wierzbicki AS, James R, Christ ER.

    Diabetes Metab Res Rev. 2007 Jul;23(5):392-9.PMID: 17211855 [PubMed - indexed for MEDLINE]Related articles

    16.

    Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes.

    Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC.

    J Clin Endocrinol Metab. 2001 Mar;86(3):1410-7.PMID: 11238540 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Hepatic fat content is a determinant of postprandial triglyceride levels in type 2 diabetes mellitus patients with normal fasting triglyceride.

    Nimitphong H, Phongkitkarun S, Rattarasarn C, Kongsooksai A, Chanprasertyothin S, Bunnag PA, Puavilai G.

    Metabolism. 2008 May;57(5):644-9.PMID: 18442627 [PubMed - indexed for MEDLINE]Related articles

    19.

    [Pioglitazone hydrochloride monotherapy or in combination with sulfonylurea therapy improves glycemia control in patients with type 2 diabetes]

    Yu Y, Li Y, Fan J, Wang Y, Yu H, Wang C, Liao Z, Gao H, Zhao W.

    Sichuan Da Xue Xue Bao Yi Xue Ban. 2003 Jan;34(1):117-20. Chinese. PMID: 15600200 [PubMed - indexed for MEDLINE]Related articles

    20.

    Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.

    Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA.

    Diabetes Care. 2006 Nov;29(11):2371-7.PMID: 17065670 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity